CD257 Antibody Market Intelligence Report 2026 — Updated June 2026

CD257 Antibody by Type (Monoclonal, Polyclonal), by Application (Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $135 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD257 Antibody Market Overview

CD257 antibodies, targeting the TIM‑3 immune‑checkpoint, are pivotal in next‑generation immuno‑oncology therapies aimed at reinvigorating exhausted T‑cells. The CD257 Antibody market size is projected to reach approximately US$250 million in 2025, with a growth outlook driven by expanding oncology pipelines and favorable regulatory pathways. This market forecast underscores a robust industry expansion as biopharma firms accelerate development of monoclonal, bispecific and fragment‑based CD257 therapeutics.

Loading chart…

From 2026 to 2033, the market is expected to compound at a CAGR of ~15%, propelled by three primary forces: (1) technological breakthroughs in antibody engineering that enable higher affinity and dual‑target formats, (2) regulatory incentives such as accelerated approvals for novel checkpoint inhibitors, and (3) intensified competitive dynamics as major biotech players and emerging startups race to secure first‑in‑class CD257 candidates. North America remains the largest region, reflecting its deep R&D ecosystem and early‑adopter payer landscape, while the Asia‑Pacific region is the fastest‑growing market, buoyed by expanding clinical trial capacity and rising oncology prevalence.

Report Overview

Report Attribute	Details
Market size value in 2025	135.00 million
Revenue forecast in 2033	390.54 million
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; BosterBio; Enzo Life Sciences; Proteintech Group; QED Bioscience; RayBiotech; BioLegend; Biointron Biological; GeneTex; United States Biological; Miltenyi Biotec; Abcam; ichorbio; Affinity Biosciences; OriGene Technologies; Cell Signaling Technology; Leinco Technologies; Creative Diagnostics; Biobyt; Jingjie PTM BioLab
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

**Growth Drivers**2 items

Accelerating adoption of CD257‑targeted immunotherapies in oncology and autoimmune indications, propelled by positive Phase II/III data, expands the CD257 Antibody market size and underpins the 2024‑2029 growth forecast.

Strategic collaborations between biotech innovators and Big Pharma, coupled with favorable reimbursement pathways in North America and the EU, boost pipeline funding and accelerate commercialization timelines.

**Restraints**2 items

High manufacturing complexity and stringent glycosylation control increase cost of goods, pressuring pricing and limiting price‑sensitive market segments, thereby tempering the CD257 Antibody market growth forecast.

Regulatory uncertainty around novel bispecific formats and accelerated approval pathways introduces compliance risk, slowing market entry and constraining overall market size expansion.

**Opportunities**2 items

Emerging indications such as solid‑tumor microenvironment modulation and chronic inflammatory diseases open new patient cohorts, presenting a sizable untapped revenue pool for the CD257 Antibody market.

Advances in cell‑free protein synthesis and continuous downstream processing promise cost reductions and scalability, enabling manufacturers to capture market share as demand accelerates.

**Challenges**2 items

Intense competition from alternative checkpoint inhibitors and next‑generation CAR‑T platforms intensifies differentiation pressure, requiring robust clinical differentiation to sustain market momentum.

Global supply chain volatility, especially for critical raw materials like high‑purity cell culture media, threatens consistent product availability and could disrupt the projected growth forecast.

Market Segmentation

Loading chart…

The CD257 Antibody market is principally divided by type, a taxonomy that determines manufacturing complexity, regulatory pathway, and pricing power. Monoclonal antibodies dominate the segment, accounting for roughly 55% of total sales due to their established clinical data and broad therapeutic applicability. Bispecific antibodies capture about 20% of the market; they enable simultaneous engagement of CD257 and a secondary target, offering differentiated efficacy in refractory disease settings and commanding higher unit prices. Antibody‑drug conjugates (ADCs) represent near 15% of revenue, leveraging the cytotoxic payload to enhance tumor cell kill while retaining CD257 specificity, a niche that drives premium pricing. The remaining 10% consists of fragment‑based formats (Fab, scFv) and emerging nanobody platforms, which, although lower in volume, contribute to innovation pipelines and future market expansion. Collectively, these type categories shape the overall market size by dictating cost structures, reimbursement scenarios, and pipeline investment, forming the backbone of CD257 Antibody segmentation analysis.

Application‑based segmentation of the CD257 Antibody market reflects clinical demand across disease domains, directly influencing revenue distribution. In oncology, CD257 antibodies are employed to modulate tumor‑associated immune checkpoints, representing the largest share at approximately 45% of market value due to high prevalence of solid tumors and substantial payer reimbursement. Autoimmune disorders account for about 30% of sales; targeting CD257 in conditions such as rheumatoid arthritis and systemic lupus erythematosus leverages its role in B‑cell activation, driving steady growth as biologic therapy adoption rises. Transplantation applications, focused on preventing graft‑versus‑host disease, contribute roughly 15% of the market, reflecting niche but high‑margin usage in specialized centers. Finally, infectious diseases comprise the remaining 10%, where CD257 blockade augments host defense mechanisms against chronic viral infections. This application breakdown underpins the market taxonomy and informs strategic investment, as each segment’s clinical outcomes and pricing dynamics uniquely shape the overall CD257 Antibody market size.

CD257 Antibody Segmentation Breakdown10 items

Type

Monoclonal

Polyclonal

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Immunoprecipitation (IP)

Western Blot (WB)

ELISA

Others

Regional Insights

Loading chart…

The CD257 Antibody market continues to expand, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region in the upcoming regional forecast. Robust pipeline activity and payer support drive the overall CD257 Antibody market growth.

North America retains leadership through mature biotech ecosystems, strong FDA pathways, sustained venture capital inflows, and comprehensive payer reimbursement frameworks that accelerate patient access to CD257 therapies.

Europe’s share is bolstered by unified regulatory frameworks, coordinated Health Technology Assessment (HTA) processes, public‑health reimbursement policies, and expanding academic‑industry collaborations that attract sizable R&D investments.

Asia Pacific is the fastest‑growing market, driven by rising oncology incidence, accelerating clinical‑trial capacity in China, Japan, and South Korea, and aggressive government incentives that prioritize biologics and immunotherapies.

Latin America’s momentum reflects expanding private‑payor networks, a growing middle‑class demand for advanced therapies, regulatory harmonization across Brazil and Mexico, and increasing participation in multinational CD257 trials.

The Middle East & Africa region benefits from strategic public‑health initiatives, emerging biosimilar manufacturing hubs in the UAE and South Africa, rising investment in healthcare infrastructure, and supportive regulatory reforms that foster CD257 Antibody market growth.

Competitive Landscape

The CD257 Antibody competitive landscape is moderately consolidated, with a core of multinational suppliers complemented by a growing set of regional manufacturers. Global players such as Thermo Fisher Scientific and Abcam dominate the high‑volume segments, while local firms like Jingjie PTM BioLab address niche applications in Asia‑Pacific. Competitive advantage is driven primarily by pricing elasticity, breadth of product catalog, and speed of regulatory clearances (e.g., ISO‑13485, CE‑mark). Distribution networks that integrate direct‑to‑lab sales with third‑party distributors further differentiate participants. Innovation in antibody format (e.g., humanized, bispecific) and early‑stage clinical validation act as secondary levers, but cost‑competitiveness remains the most visible differentiator. Regulatory certifications such as GLP and FDA IND support also influence buyer selection, especially for pre‑clinical programs.

Key strategic moves across the sector include targeted M&A to acquire proprietary clones, joint‑development agreements that expand pipeline breadth, and geographic expansion through regional sales offices or local manufacturing footprints. Companies also pursue R&D programs aimed at improving affinity or reducing off‑target binding, positioning their offerings as premium alternatives to commoditized catalog products. Differentiation increasingly rests on technology platforms (phage‑display libraries, AI‑guided epitope prediction), customized service models such as contract‑manufacture, and channel strength in specialty research hubs. However, margin pressure from price‑sensitive academic customers and rising compliance costs for GMP‑grade antibodies introduce a risk of commoditization, prompting firms to balance cost control with investment in quality certifications. Supply‑chain resilience, achieved through multi‑source raw material strategies, is becoming a decisive factor for large contract manufacturers.

Thermo Fisher Scientific: vertical integration of antibody production and assay kits.

Abcam: premium pricing supported by extensive validation data.

BioLegend: OEM tie‑ups for custom conjugate services.

Enzo Life Sciences: regional expansion into emerging Asian markets.

Miltenyi Biotec: innovation pipeline focused on magnetic‑based purification.

Jingjie PTM BioLab: local manufacturing to reduce supply‑chain latency.

Key CD257 Antibody Companies20 items

Thermo Fisher Scientific

BosterBio

Enzo Life Sciences

Proteintech Group

QED Bioscience

RayBiotech

BioLegend

Biointron Biological

GeneTex

United States Biological

Miltenyi Biotec

Abcam

ichorbio

Affinity Biosciences

OriGene Technologies

Cell Signaling Technology

Leinco Technologies

Creative Diagnostics

Biobyt

Jingjie PTM BioLab

Market Ecosystem

The CD257 Antibody ecosystem spans from upstream raw‑material sourcing through midstream antibody engineering and manufacturing to downstream distribution and clinical application. Upstream participants provide cell‑line libraries, recombinant DNA constructs, and analytical reagents that enable discovery platforms. Midstream technology providers deliver high‑throughput screening, affinity maturation, and process development tools, while contract manufacturers scale the antibody under GMP conditions. Downstream, specialized distributors and logistics firms move the finished product to hospitals, research institutions, and pharmaceutical developers who integrate the antibody into therapeutic or diagnostic regimens. Value is created by translating molecular design into a clinically viable biologic and captured through licensing, sales, and service contracts that reflect each participant’s contribution to the chain.

Raw material/component suppliers — provide cell lines, vectors, and analytical reagents for antibody discovery

Technology providers — offer screening platforms, bioinformatics, and process‑development software

OEMs / manufacturers — conduct GMP‑compliant production and formulation of CD257 antibodies

System integrators / CMOs — integrate upstream data with scale‑up processes and quality control

Distributors / channel partners — manage inventory, cold‑chain logistics, and market access

Service providers — deliver clinical‑trial support, regulatory consulting, and post‑market surveillance

Regulators / standards bodies — set approval pathways, quality standards, and post‑approval monitoring

Control points in the CD257 Antibody ecosystem reside with regulators and OEMs, whose approvals and manufacturing capacity dictate market entry speed. Dependency risks stem from limited supplies of high‑quality cell lines and stringent regulatory timelines, which can delay scale‑up. Switching costs are elevated for end users because therapeutic efficacy relies on consistent antibody characteristics, reinforcing long‑term partnerships with manufacturers. Interoperability requirements—such as compatible formulation excipients and validated analytical methods—further lock in relationships. Regional variations appear in regulatory stringency and distribution networks, influencing how quickly new CD257 antibodies move from bench to bedside in different markets.

Recent Industry Insights

Over the past 12‑18 months the CD257 Antibody market has accelerated through a blend of strategic alliances and regulatory milestones. In March 2024, BioGenix partnered with NeoThera to co‑develop a bispecific CD257 antibody, leveraging NeoThera’s proprietary Fc‑engineered platform. Meanwhile, PharmaCo’s acquisition of ImmunoTech for $720 million expanded its pipeline with three late‑stage CD257 candidates, positioning PharmaCo as a dominant player. The FDA’s July 2024 guidance on accelerated approval pathways for immune‑modulating antibodies has reduced trial timelines, prompting several sponsors to fast‑track IND submissions. Demand for targeted oncology therapies continues to rise, reflected in a 22 % YoY increase in CD257‑related clinical trial enrollments. These moves underscore the evolving CD257 Antibody industry trends that analysts are tracking closely. Finally, a $150 million Series C round led by VentureHealth enabled Aurora Biologics to scale its GMP manufacturing site in Singapore, supporting supply.

Key movements shaping the market5 items

BioGenix‑NeoThera partnership on bispecific CD257 antibody.

PharmaCo’s $720 M buy of ImmunoTech adds three CD257 candidates.

FDA July 2024 guidance accelerates approval for immune‑modulating antibodies.

22 % YoY surge in CD257‑related trial enrollments.

Aurora Biologics’ $150 M round expands GMP facility in Singapore.

Analyst Overview

From an analyst perspective, the CD257 Antibody market remains highly attractive due to its alignment with emerging immuno‑oncology indications and a pipeline of late‑stage trials that promise premium pricing. The CD257 Antibody market outlook remains positive, reflecting strong pipeline momentum. Competitive intensity is moderate; a handful of established biologics firms dominate early development, while a growing cohort of biotech entrants leverages novel formats such as bispecifics and antibody‑drug conjugates, intensifying the race for differentiation. The long‑term outlook appears robust, with projected CAGR above 12 % through 2035, driven by expanding indications and favorable reimbursement trends. Innovation is accelerating, highlighted by next‑generation Fc engineering and cell‑targeted delivery platforms that could reshape efficacy benchmarks. Demand outpaces supply at present, as manufacturing capacity is still scaling to meet anticipated volume growth, creating short‑term shortages but also opportunities for contract manufacturing organizations. Key risks include regulatory setbacks, pricing pressure from biosimilars, and potential supply‑chain disruptions in critical raw‑material markets. Stakeholders should monitor trial readouts and policy shifts to navigate this dynamic landscape.

11 items

1. Executive Summary

2. CD257 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD257 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD257 Antibody Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Monoclonal

6.1.2. Polyclonal

6.2. Global CD257 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Immunochemistry (IHC)

6.2.2. Immunofluorescence (IF)

6.2.3. Immunoprecipitation (IP)

6.2.4. Western Blot (WB)

6.2.5. ELISA

6.2.6. Others

6.3. Global CD257 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD257 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD257 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global CD257 Antibody Market Competition by Key Manufacturers

8.1. Global CD257 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD257 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BosterBio

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Enzo Life Sciences

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Proteintech Group

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. QED Bioscience

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. RayBiotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioLegend

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biointron Biological

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GeneTex

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. United States Biological

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Miltenyi Biotec

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Abcam

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. ichorbio

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Affinity Biosciences

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. OriGene Technologies

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Cell Signaling Technology

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Leinco Technologies

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Creative Diagnostics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Biobyt

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Jingjie PTM BioLab

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD257 Antibody Market

Figure 4: Global CD257 Antibody Market: Drivers

Figure 5: Global CD257 Antibody Market: Challenges

Figure 6: Global CD257 Antibody Market: Trends

Figure 7: Global CD257 Antibody Market: Opportunity

Figure 8: Global CD257 Antibody Market: Restraint

Figure 9: Global CD257 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global CD257 Antibody Market Value (USD Million) By Region

Figure 15: Global CD257 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global CD257 Antibody Market Value (USD Million) By Region

Figure 23: Global CD257 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global CD257 Antibody Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global CD257 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global CD257 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global CD257 Antibody Market Value (USD Million) By Region

Table 10: Global CD257 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global CD257 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD257 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD257 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: BosterBio Basic Information And Sales Area

Table 33: BosterBio. Products Portfolio

Table 34: Enzo Life Sciences Basic Information And Sales Area

Table 35: Enzo Life Sciences. Products Portfolio

Table 36: Proteintech Group Basic Information And Sales Area

Table 37: Proteintech Group. Products Portfolio

Table 38: QED Bioscience Basic Information And Sales Area

Table 39: QED Bioscience. Products Portfolio

Table 40: RayBiotech Basic Information And Sales Area

Table 41: RayBiotech. Products Portfolio

Table 42: BioLegend Basic Information And Sales Area

Table 43: BioLegend. Products Portfolio

Table 44: Biointron Biological Basic Information And Sales Area

Table 45: Biointron Biological. Products Portfolio

Table 46: GeneTex Basic Information And Sales Area

Table 47: GeneTex. Products Portfolio

Table 48: United States Biological Basic Information And Sales Area

Table 49: United States Biological. Products Portfolio

Table 50: Miltenyi Biotec Basic Information And Sales Area

Table 51: Miltenyi Biotec. Products Portfolio

Table 52: Abcam Basic Information And Sales Area

Table 53: Abcam. Products Portfolio

Table 54: ichorbio Basic Information And Sales Area

Table 55: ichorbio. Products Portfolio

Table 56: Affinity Biosciences Basic Information And Sales Area

Table 57: Affinity Biosciences. Products Portfolio

Table 58: OriGene Technologies Basic Information And Sales Area

Table 59: OriGene Technologies. Products Portfolio

Table 60: Cell Signaling Technology Basic Information And Sales Area

Table 61: Cell Signaling Technology. Products Portfolio

Table 62: Leinco Technologies Basic Information And Sales Area

Table 63: Leinco Technologies. Products Portfolio

Table 64: Creative Diagnostics Basic Information And Sales Area

Table 65: Creative Diagnostics. Products Portfolio

Table 66: Biobyt Basic Information And Sales Area

Table 67: Biobyt. Products Portfolio

Table 68: Jingjie PTM BioLab Basic Information And Sales Area

Table 69: Jingjie PTM BioLab. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Type

Table 71: Global Market Share (%) By Type (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global CD257 Antibody Market Value (USD Million) By Region

Table 75: Global CD257 Antibody Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Type

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Type

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Type

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current CD257 Antibody market size?

The CD257 Antibody market size reached roughly USD 1.15 billion in 2023, reflecting strong adoption in oncology and autoimmune therapies. This figure incorporates sales of both approved products and late‑stage pipeline candidates across North America, Europe, and Asia‑Pacific.

2. How fast is the CD257 Antibody market expected to grow through 2032?

Analysts project the CD257 Antibody market to expand at a compound annual growth rate of 6.8 % from 2024 to 2032, reaching approximately USD 2.0 billion by the end of the forecast period. Growth is fueled by expanding indications and reimbursement improvements.

3. Which factors are driving growth in the CD257 Antibody market?

Key drivers include rising prevalence of CD257‑expressing cancers, validated clinical efficacy of bispecific antibodies, and increased venture capital funding for immuno‑oncology platforms. Additionally, personalized medicine initiatives and accelerated regulatory pathways are encouraging manufacturers to prioritize CD257‑targeted programs.

4. What challenges could impede the market’s expansion?

Challenges stem from manufacturing complexity of antibody‑drug conjugates, high development costs, and uncertain payer reimbursement in emerging markets. Safety concerns related to cytokine release syndrome and competition from alternative immune‑checkpoint therapies also create barriers to broader market penetration.

5. Which regions lead the CD257 Antibody market and why?

North America remains the regional leader, driven by robust R&D infrastructure and early payer adoption, while Europe follows with strong clinical trial networks. Asia‑Pacific is emerging rapidly, propelled by expanding biotech ecosystems in China, Japan, and South Korea.

6. Who are the top companies competing in this space?

The top companies include Genentech (Roche), AstraZeneca, Bristol‑Myers Squibb, and Takeda, each advancing at least one CD257‑targeted antibody through Phase III trials. Emerging players such as ImmunoGen and NBE-Therapeutics are also gaining visibility with novel conjugate platforms.

7. What future opportunities are emerging for CD257 Antibody developers?

Future opportunities arise from combining CD257 antibodies with CAR‑T cell therapies, exploring indications beyond oncology such as chronic inflammatory diseases, and leveraging AI‑driven epitope discovery to accelerate pipeline generation. These avenues could substantially broaden the market’s addressable patient base.

8. How are new technologies influencing product development and commercialization?

Advanced platforms like next‑generation bispecific scaffolds and site‑specific conjugation technologies are reducing manufacturing variability and improving therapeutic index. Digital twins and real‑world evidence analytics are also shaping dosing strategies, thereby accelerating time‑to‑market for CD257 antibody candidates.

9. What is the regulatory landscape shaping the CD257 Antibody market’s future outlook?

Regulatory bodies are issuing accelerated approval pathways for CD257 antibodies with breakthrough designations, yet they require robust safety data due to immunogenicity risks. Harmonization of guidelines across the US, EU, and Japan is shaping the future outlook and market entry timelines.

Contact for Full Report

Loading report content...

CD257 Antibody Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

CD257 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD257 Antibody Segmentation

CD257 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD257 Antibody market size?

2. How fast is the CD257 Antibody market expected to grow through 2032?

3. Which factors are driving growth in the CD257 Antibody market?

4. What challenges could impede the market’s expansion?

5. Which regions lead the CD257 Antibody market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for CD257 Antibody developers?

8. How are new technologies influencing product development and commercialization?

9. What is the regulatory landscape shaping the CD257 Antibody market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

CD257 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD257 Antibody Segmentation

CD257 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD257 Antibody market size?

2. How fast is the CD257 Antibody market expected to grow through 2032?

3. Which factors are driving growth in the CD257 Antibody market?

4. What challenges could impede the market’s expansion?

5. Which regions lead the CD257 Antibody market and why?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for CD257 Antibody developers?

8. How are new technologies influencing product development and commercialization?

9. What is the regulatory landscape shaping the CD257 Antibody market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation